All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia

European Journal of Haematology

Volumn 64, Issue 3, 2000, Pages 139-144

  Visani, Giuseppe ^a   Gugliotta, Luigi ^b   Tosi, Patrizia ^b   Catani, Lucia ^b   Vianelli, Nicola ^b   Martinelli, Giovanni ^b   Ottaviani, Emanuela ^b   Testoni, Nicoletta ^b   Nocentini, Franco ^b   Pastano, Rocco ^b   Piccaluga, Pierpaolo ^b   Isidori, Alessandro ^b   Grafone, Tiziana ^b   Tura, Sante ^b  

^a Istituto di Ematologia Ed Oncologia Medica L e A Seragnoli   (Italy)

^b NONE

Author keywords

Acute leukemia; All trans retinoic acid; Early death; Hemorrhage; Promyelocytic

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; D DIMER; DAUNORUBICIN; IDARUBICIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CYTARABINE; DAUNORUBICIN; HEMORRHAGE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRETINOIN;

EID: 0034071177     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.09001.x     Document Type: Article

References (24)

1. 1. FENAUX P, CASTAIGNE S, DOMBRET H. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remission in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80:2176-2181.
2. 2. FENAUX P, LE DELEY C, CASTAIGNE C, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-3249.
3. 3. MANDELLI F, DIVERIO D, AVVISATI G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-1024.
4. 4. TALLMAN MS, ANDERSEN JW, SCHIFFER CA, et al. A prospective randomized study of all-trans retinoic acid induction and maintenance therapy for patients with acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.
5. 5. BARBUI T, FINAZZI G, FALANGA A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-3102.
6. 6. FRANKEL SR, EARDLEY A, HELLER G. All-trans retinoic acid for acute promyelocytic leukemia. Ann Int Med 1994;120: 278-286.
7. 7. KANAMARU A, TAKEMOTO Y, TANIMOTO M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85:1202-1206.
8. 8. ESTEY E, THALL PF, PIERCE S, KANTARJIAN H, KEATING M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15:483-490.
9. 9. AVVISATI G, LO COCO F, DIVERIO D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a "Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA)" pilot study. Blood 1996;88:1390-1397.
10. 10. AVVISATI G, MANDELLI F, PETTI MC, et al. Idarubicin as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Hematol 1990;44: 257-260.
11. 11. KAPLAN EL, MEIER P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
12. 12. PETO R, PIKE MC, ARMITAGE NE, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. Br J Cancer 1977;35:1-39.
13. 13. RODEGHIERO F, AVVISATI G, CASTAMAN G, BARBUI T, MANDELLI F. Early deaths and anti-hemorragic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990;75:2112-2117.
14. 14. TALLMAN MS, KWAAN CM. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-553.
15. 15. WARRELL RP, dE THE H, WANG Z-Y, DEGOS L. Acute promyelocytic leukemia. N Engl J Med 1993;392:177-191.
16. 16. TORNEBOHM E, LOCKNER D, PAUL C. A retrospective analysis of bleeding complications in 438 patients with acute leukemia during the years 1972-1991. Eur J Haematol 1993; 50:160-167.
17. 17. DOMBRET H, SCROBOHACI ML, GHORRA P, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effects of all-trans retinoic acid. Leukemia 1993;7:2-14.
18. 18. KAWAY Y, WATANABE K, KIZAKI M, et al. Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1994;46:184-188.
19. 19. DEGOS L, DOMBRET H, CHOMIENNE C. all-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-2653.
20. 20. DE STEFANO V, TEOFILI L, SICA S, et al. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995;86:3535-3543.
21. 21. FALANGA A, IACOVIELLO L, EVANGELISTA V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans retinoic acid. Blood 1995;86:1072-1081.
22. 22. DOMBRET H, SCROBOHACI ML, DANIEL MT, et al. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995;9:19-24.
23. 23. HECKMAN KD, WEINER GJ, DAVIS CS, STRAUSS RG, JONES MP, BURNS P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol 1997;15:1143-1149.
24. 24. MENELL JS, CESARMAN GM, JACOVINA AT, MCLAUGHLIN MA, LEV EA, HAJJAR KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004.